Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma

Laboratory Investigation

Volumn 83, Issue 6, 2003, Pages 861-870

  Horiuchi, Akiko ^a   Imai, Tsutomu ^a   Wang, Cuiju ^a   Ohira, Satoshi ^a   Feng, Yuzhen ^a   Nikaido, Toshio ^a   Konishi, Ikuo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; GUANOSINE TRIPHOSPHATASE; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN; SMALL GUANOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CYSTADENOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROUS CARCINOMA; TUMOR GROWTH;

EID: 0038679226     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000073128.16098.31     Document Type: Article

References (35)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson JM, Kozlowski JM, and McEwan RN (1987). A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245.
2. Avraham H and Weinberg RA (1989). Characterization and expression of the human rhoH12 gene product. Mol Cell Biol 9:2058-2066.
3. Baserga R (1994). Oncogenes and the strategy of growth factors. Cell 79:927-930.
4. Bernstein LR and Liotta LA (1994). Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 6:106-113.
5. Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ, and Gill DM (1989). The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. EMBO J 8:1087-1092.
6. Chomczynski P and Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 162:156-159.
7. Clark EA, Golub TR, Lander ES, and Hynes RO (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535.
8. Fishman DA, Liu Y, Ellerbroek SM, and Stack MS (2001). Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61:3194-3199.
9. Fritz G and Aktories K (1994). ADP-ribosylation of Rho proteins by Clostridium botulinum exoenzyme C3 is influenced by phosphorylation of Rho-associated factors. Biochem J 300:133-139.
10. Fritz G, Just I, and Kaina B (1999). Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682-687.
11. Goetzl EJ and An S (1998). Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 12:1589-1598.
12. Hall A (1998). Rho GTPases and the actin cytoskeleton. Science 279:509-514.
13. Horiuchi A, Imai T, Shimizu M, Oka K, Wang C, Nikaido T, and Konish I (2002). Hypoxia-induced changes in the expression of VEGF, HIF-1α and cell cycle-related molecules in ovarian cancer cells Anticancer Res 22:2697-2702.
14. Horiuchi A, Nikaido T, Ito K, Zhai Y, Orii A, Taniguchi S, and Fujii S (1998). Reduced expression of calponin h1 in leiomyosarcoma of the uterus. Lab Invest 78:839-846.
15. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, and Jaffe RB (2001). Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762-768.
16. Jaffe AB and Hall A (2002). Rho GTPases in transformation and metastasis. In: Vande Woude G and Klei G, editors. Advances in cancer research, vol 84. San Diego: Academic Press, 57-80.
17. Kamai T, Arai K, Tsujii T, Honda M, and Yoshida K (2001). Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 87:227-231.
18. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, and Merajver SD (2002). Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160:579-584.
19. Mandai M, Konishi I, Komatsu T, Mori T, Arao S, Nomura H, Kanda Y, Hiai H, and Fukumoto M (1995). Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: Correlation with tumour progression and nm23 gene expression. Br J Cancer 72:691-695.
20. Morrow CP and Curtin JP (1998). Tumor of the ovary: Neoplasms derived from celomic epithelium. In: Synopsis of gynecologic oncology. Fifth editor. New York: Churchill Livingstone.
21. National Institutes of Health (1994). Ovarian cancer: Screening, treatment, and follow up. NIH Consensus Statement 12:1-30.
22. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, and Lengyel E (2001). Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7:2396-2404.
23. Scully RE, Young RH, and Clement PB (1998). Surface epithelial-stromal tumors and serous tumors. In: Tumor of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, Third series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology, 51-79.
24. Skubitz AP (2002). Adhesion molecules. Cancer Treat Res 107:305-329.
25. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, and Fukumoto M (1998). Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77:147-152.
26. Van Aelst L and D'Souza-Schorey C (1997). Rho GTPases and signaling networks. Genes Dev 11:2295-2322.
27. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, and Merajver SD (1999). A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5:2511-2519.
28. van Golen KL, Wu ZF, Qiao XT, Bao LW, and Merajver SD (2000). RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832-5838.
29. Xu Y, Fang XJ, Casey G, and Mills GB (1995a). Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309:933-940.
30. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, et al (1995b). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1:1223-1232.
31. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, and Casey G (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723.
32. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, and Mori T (1997). Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227.
33. Yoshioka K, Matsumura F, Akedo H, and Itoh K (1998). Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 27:5146-5154.
34. Yoshioka K, Nakamori S, and Itoh K (1999). Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 59:2004-2010.
35. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, and Rodenhuis S (1998). Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437-442.